Tirzepatide, a novel treatment agent, has emerged as a groundbreaking discovery in the realm of GLP-1 receptor agonism. Unlike previous GLP-1 receptor agonists, tirzepatide exerts its effects by simultaneously stimulating both the GLP-1 and GIP receptors. This dual mechanism of action enhances a morerobust reduction in blood sugar, leading to impro